In February 2023, Russian manufacturers produced 100.1 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 12.6% from February 2022.

In 2022, the online sales or reservations of pharmaceutical products (pharmaceutical drugs and parapharmaceuticals) in Russia were 294.6 billion rubles (end-user prices, VAT included), 40.3% up from 2021, when the growth rate was 53%.

2022 Ranking of Russian Pharmacy Chains.

2022 Ranking of Russian Pharmaceutical Distributors.

In early February, branches of the Social Fund of the Russian Federation began distributing special payments to doctors as part of a government program to support healthcare workers.

In 2022, Russia imported 15.9 billion rubles’ worth of veterinary vaccines (EEU imports excluded; customs clearance and VAT included), up 3.4% from 2021)—practically the same as in the past three years. In physical terms, 7 million packages were imported, up 14.9% from 2021. If calculated in doses, the import was 21.7 billion, up 19.8% from 2021.

In 2022, Russia imported 38.2 billion rubles’ worth of veterinary drugs (customs clearance and VAT included; imports from EEU countries excluded), up only 2.8% from 2021, although the import volume was record-worthy. In physical terms, Russia imported around 34.1 million packages, up 7.1% from 2021. As for feed supplements, imports went down 5.2%, with 41 billion rubles’ worth of products. In physical terms, Russia imported 149,700 tons, down 7.7% from 2021.

In 2022, Russia imported 838.9 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 6.2% from 2021. In physical terms, imports went down 8.7%, which is not that bad, considering all the sanctions, sharp demand fluctuations, and a very high base in 2021. As for bulk drugs, the import volume was 184 billion rubles, up 9.2% from 2021. In physical terms, however, imports decreased 34.3% in minimum dosage units (MDU), with 1.49 billion MDUs imported.

In 2022, Russian manufacturers produced 668.8 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 7.1% from 2021. In physical terms, the manufacture went up only 1%, with around 4.17 billion packages produced. The average package remained more or less the same, which is why the growth rate in minimum dosage units (MDU) was 1.7%, with 79.6 billion MDUs manufactured.

In 2022, Russia imported 191.6 billion rubles’ worth of APIs (customs clearance and VAT included), down 4.2% from 2021 for the first time in 12 years. This is the result of a significant reduction in prices for raw materials with the ruble strengthening, rather than the import falling in physical terms. On the contrary, the import grew by as much as 18.8% in physical terms, with 20,800 tons of pharmacopoeial and commercial APIs imported.